The Bank of Japan is reportedly considering pausing its bond purchase reduction for the next fiscal year, a move that would halt its quantitative tightening (QT) plans. This potential pause stems from internal disagreements within the nine-member policy board, with some members prioritizing investor sentiment and others advocating for a steady reduction of the central bank's balance sheet. Separately, a new investment fund, Jinan Fuhui Xing Weilai Medical Investment Management Partnership, has been established with a capital of 75.01 million RMB, involving entities under Fosun Pharma. AI
RANK_REASON The article discusses potential policy shifts and new investment fund formations, but does not announce a new model, research, or significant industry-wide event.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →